Details
| Stereochemistry | MIXED |
| Molecular Formula | 2C18H25NO2.C4H6O6 |
| Molecular Weight | 724.88 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 8 / 8 |
| E/Z Centers | 0 |
| Charge | 0 |
| Stereo Comments | Moxazocine is racemic and Tartaric acid chiral |
SHOW SMILES / InChI
SMILES
O[C@H]([C@@H](O)C(O)=O)C(O)=O.CO[C@H]1[C@H]2CC3=CC=C(O)C=C3[C@]1(C)CCN2CC4CC4.CO[C@H]5[C@H]6CC7=CC=C(O)C=C7[C@]5(C)CCN6CC8CC8
InChI
InChIKey=PUBVUBRYUIOBTJ-DAORBUFXSA-N
InChI=1S/2C18H25NO2.C4H6O6/c2*1-18-7-8-19(11-12-3-4-12)16(17(18)21-2)9-13-5-6-14(20)10-15(13)18;5-1(3(7)8)2(6)4(9)10/h2*5-6,10,12,16-17,20H,3-4,7-9,11H2,1-2H3;1-2,5-6H,(H,7,8)(H,9,10)/t2*16-,17+,18+;1-,2-/m111/s1
Moxazocine is a benzomorphan derivative patented by Bristol-Myers Co. as potent opioid analgesic. Moxazocine acts as a partial agonist or mixed agonist/antagonist of the opioid receptors and binds preferentially to the κ-opioid receptor. In clinical studies, Moxazocine demonstrated superior efficacy compared morphine, but was never marketed.
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
U208HJA2N3
Created by
admin on Tue Apr 01 22:00:31 GMT 2025 , Edited by admin on Tue Apr 01 22:00:31 GMT 2025
|
PRIMARY | |||
|
58266-96-9
Created by
admin on Tue Apr 01 22:00:31 GMT 2025 , Edited by admin on Tue Apr 01 22:00:31 GMT 2025
|
PRIMARY |
SUBSTANCE RECORD
